Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

Douxfils, Jonathan; Haguet, Hélène; Mullier, François; Chatelain, C; Graux, Carlos; Dogné, Jean‐Michel

doi:10.1001/jamaoncol.2015.5932

Public

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

Published in JAMA Oncology • Feb 5, 2016

Authors:

Jonathan Douxfils

Hélène Haguet

François Mullier

Abstract

IMPORTANCE: A phase 3 trial with ponatinib in patients with chronic myeloid leukemia (CML) was interrupted due to an important increase of vascular occlusive events. A similar risk was also suspected with nilotinib, another BCR-ABL tyrosine kinase inhibitor (TKI) used in patients with CML. OBJECTIVE...

Subject

Medicine

Nilotinib

Dasatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!